Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis

Background: Pediatric multiple sclerosis (MS) is rare: only 1.5–5% of MS cases are diagnosed before 18 years of age, and data on disease-modifying therapies (DMTs) for pediatric MS are limited. The CONNECTED study assessed the long-term safety and efficacy of treatment with delayed-release dimethyl...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Neurol
Asıl Yazarlar: Alroughani, Raed, Huppke, Peter, Mazurkiewicz-Beldzinska, Maria, Blaschek, Astrid, Valis, Martin, Aaen, Gregory, Pultz, Joe, Peng, Xiaomei, Beynon, Vanessa
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Neurology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7812971/
https://ncbi.nlm.nih.gov/pubmed/33473248
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2020.606418
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller